glp-1 drugs kidney disease Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Frontiers | GLP-1 Receptor Agonists
Description
Prevention of just 1% of these cases would save the healthcare system an estimated $13.8B
The TGA, Australias medicines regulator, would not comment directly on the UNSW analysis but urged consumers to exercise extreme caution
In clinical trials, the results are modest but real
By hindering this proteins function, Jardiance allows for more glucose to be excreted in urine, helping to lower blood glucose levels
iScience (2021) 24:103382
